CMP-CPS-001 has secured FDA Orphan Drug and Rare Pediatric Disease Designations for urea cycle disorders. Last month, the company announced a new research collaboration with BioMarin Pharmaceutical Inc ( BMRN ) to advance novel therapeutics that increase protein levels by targeting regulatory RNA (...
which is the first of our HCAb molecules to be tested in the clinics. The preclinical and clinical results so far have been encouraging and with these approvals, we aim to expand the use of HBM4003 in Chinese patients and in combination therapy." said Dr. Jingsong...